Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-086293
Chunk: 20

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 20
---
 Engineering & Biotechnology News. Mr. Bode responded to Mr. Elko’s email thanking him for being a stockholder of the Company and sharing his perspective.

On January 20, 2024, Alvin Shih, M.D. was appointed as a director, following a recommendation from the Nominating and Corporate Governance Committee, after being initially identified through a third-party search firm.

<div align='center'>21</div>

Seven of the Company’s eight current directors joined the Board on or after the 2023 Annual Meeting, inclusive of the three directors Mr. Mangless nominated for election at the 2023 Annual Meeting.

On January 22, 2024, Mr. McFarlane met with Dr. Mickle for dinner to discuss his consulting arrangement with the Company and the status of certain deliverables.

On March 13, 2024, Mr. McFarlane met with Dr. Mickle via teleconference to discuss the consulting arrangement with the Company and the status of certain deliverables. Dr. Mickle expressed support for the Company’s strategic direction and management’s execution. Dr. Mickle also indicated he had no interest in serving as a director unless specifically invited to do so.

On March 22, 2024, Mr. McFarlane, Mr. Clifton, and Mr. Bode met via teleconference with Mr. Elko, Mr. Mangless and Ryan Ball, a stockholder of the Company, to discuss questions raised by Mr. Elko, Mr. Mangless, and Mr. Ball in relation to the Company’s compensation and corporate governance practices.

On April 8, 2024, following requests from Mr. Elko, Mr. Clifton sent an email to Mr. Elko, copying Mr. Mangless, Mr. Ball, Mr. McFarlane, Mr. Clifton, Mr. Bode, and Tamara A. Favorito, a current director, Board Chair, and chair of the audit committee, as well as a nominee recommended by the Board for re-election at the Annual Meeting.

On June 25, 2024, Rahsaan W. Thompson was appointed as Chief Legal Officer, Secretary and Compliance Officer, and Alison Peters was appointed as Chief People Officer.

On September 20, 2024, Dr. Mickle received performance-based restricted stock units pursuant to the terms of his consulting arrangement.

On October 23, 2024, Mr. Mangless sent an email to Mr. Bode expressing satisfaction with the